Automated CAR T Cell Engineering System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of chimeric antigen receptor T (CAR T) cells is hindered by the need for significant manual involvement due to sensitive unit operations like cell activation, transduction, and expansion, which increases costs and reduces process efficiency and product consistency, making it challenging to translate these therapies into commercial-scale applications for broad patient access.
Innovation Solution
A fully-enclosed automated cell engineering system is used to automate the production of CAR T cells, optimizing processes such as activation, transduction, expansion, and harvesting, while maintaining controlled conditions to ensure consistency and efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If manual involvement is used for cell activation, transduction, and expansion, then process flexibility and adaptability are maintained, but manufacturing costs increase and product consistency deteriorates
Solution Approach 1:
The automated system performs cell activation, transduction, and expansion operations autonomously without requiring manual intervention. The system self-manages the entire CAR T cell production process including reagent addition, incubation monitoring, and cell harvesting, thereby eliminating labor costs while maintaining consistent product quality through standardized automated protocols
Solution Approach 2:
The system optimizes and controls critical process parameters such as temperature, pH, reagent concentrations, and incubation times through automated mechanisms. By precisely controlling these parameters throughout the production process, the system achieves high product consistency while reducing variability associated with manual operations
2Reliability
If manual operations are used for CAR T cell production, then process adaptability is maintained, but labor time increases and contamination risk increases
Solution Approach 1:
The automated system performs all cell culture operations in closed, sterile environments without manual opening or intervention. The system autonomously handles reagent preparation, cell manipulation, and waste removal, eliminating the need for operator presence in clean rooms and thereby minimizing contamination risks while reducing labor time requirements
Solution Approach 2:
The system uses automated liquid handling robots and closed-transfer mechanisms as intermediaries to move cells and reagents between containers. These automated intermediaries eliminate direct human contact with cell cultures, reducing contamination risk while accelerating process throughput compared to manual operations
3Productivity
If automated systems are implemented for cell therapy production, then productivity and consistency improve, but device complexity increases
Solution Approach 1:
The automated system is designed as a multi-functional platform that can perform multiple cell therapy operations including activation, transduction, expansion, and harvesting within a single integrated system. This universal design increases productivity by eliminating the need for multiple separate devices while managing complexity through standardized modular components
Solution Approach 2:
The system is divided into modular functional units or cassettes, each performing a specific operation (e.g., activation cassette, transduction cassette, expansion cassette). This segmentation allows independent optimization of each module while maintaining overall system productivity, and enables flexible reconfiguration based on production requirements
Data Source
AI summary
The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.